Accord BioPharma’s IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans
Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefit RALEIGH, N.C., April 20, 2026 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas…
Accord BioPharma’s IMULDOSA® (ustekinumab-srlf) Added to Express Scripts National Commercial Formularies
Company’s immunology franchise demonstrates strong market momentum with preferred status under one of the largest pharmacy benefit managers in the nation RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/…
Accord BioPharma Announces Commercial Launch of IMULDOSA® (ustekinumab-srlf) Prefilled Syringes at Lowest WAC Price Among Branded Biosimilars to STELARA® (ustekinumab)
Company’s third biosimilar expands access to proven targeted biologic therapy with patient-centric support services and resources RALEIGH, N.C., Aug. 18, 2025 /PRNewswire/ — Accord BioPharma,…
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth
Agreement demonstrates the expanding leadership of Accord BioPharma and Intas in the biosimilar market RALEIGH, N.C., Dec. 3, 2024 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty…
FDA Approves IMULDOSA™ (ustekinumab-srlf), Accord BioPharma’s Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
With the approval of IMULDOSA, Accord BioPharma’s biosimilar portfolio continues to grow while expanding treatment options appropriate for patients RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ –…
Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA® Biosimilar DMB-3115
Biosimilar for STELARA® (ustekinumab) seeks to treat several autoimmune disorders caused by overactive immune response DURHAM, N.C., Jan. 4, 2024 /PRNewswire/ — Accord BioPharma, Inc. the U.S….
Accord BioPharma Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
The biosimilar for Herceptin seeks to treat several forms of HER2 cancer DURHAM, N.C., April 5, 2023 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd.,…
